Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder

Condition(s) targeted: Menopause; Depression

Intervention: estrogen alone (Drug); fluoxetine alone (Drug); estrogen and fluoxetine together (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Yale University

Official(s) and/or principal investigator(s):
Cynthia N Epperson, MD, Principal Investigator, Affiliation: Yale School of Medicine

The purpose this study is to measure cortical gama-aminobutyric acid levels (GABA) levels in menopausal women with major depressive disorder and healthy subjects using nuclear magnetic resonance spectroscopy (MRS). Measurements will be compared in 1) menopausal healthy subjects before and after estrogen replacement, and after fourteen days of medroxyprogesterone administration; and 2) in depressed menopausal subjects before and after treatment of their depression with antidepressant alone, estrogen alone or antidepressant plus estrogen. Cortical GABA levels will be correlated with plasma GABA and neurosteroid levels. Neurosteroids to be measured include progesterone, allopregnanalone, pregnenolone, and pregnenolone sulfate.

Official title: Measurement of GABA and Neurosteroid Levels in Women With Menopausal Major Depression Before and After Treatment With Estrogen Alone, Fluoxetine Alone, or Estrogen and Fluoxetine and Normal Controls Before and After Treatment With Estrogen

Study design: Treatment, Non-Randomized, Open Label, Factorial Assignment

Primary outcome: Comparison of cortical GABA levels in 4 groups of subjects using estrogen alone, fluoxetine alone, estrogen and fluoxetine combined in pre and post 4.0T magnetic resonance spectroscopy sessions.

Minimum age: 40 Years. Maximum age: 70 Years. Gender(s): Female.

Criteria:

Inclusion criteria for Depressed Patients:

- Aged 40-70 years and able to give voluntary written informed consent.

- Meet DSM-IV criteria for major depression based on a structured clinical interview

(SCID).

- Have no medical contraindication to estrogen. (This will include written

documentation of a recent normal gynecological evaluation and mammogram).

- A minimum score of 25 on the 25-item Hamilton Depression Rating Scale on initial

baseline rating which does not show improvement during the one-week observation period.

- Perimenopausal subjects will be those who have had irregular menses of either <21 days

or >35 days for the previous six months to one year. Postmenopausal subjects will be those with no menstrual cycles and no hormone therapy for at least one year and serum FSH >45.

Exclusion criteria:

- Meeting DSM-IV for any other Axis I disorder.

- A history of serious medical or neurological illness, including (but not limited to)

major cardiovascular disease, severe hypertension, intracranial mass lesions, seizure disorder, severe hepatic or renal disease, unstable endocrine or metabolic disease, and unstable hematologic disease.

- A history of moderate to severe endometriosis; milder cases will require subject's

Gynecologists permission to participate.

- Use of anticonvulsants or benzodiazepines within the last month.

- Use of psychotropic medication in last week (except as stated above).

- Use of alcohol within last month.

- Current pregnancy (for the perimenopausal subjects).

- Positive urine drug screen.

- Metallic implants.

Inclusion Criteria for Healthy Subjects:

- No DSM-IV psychiatric or substance abuse diagnosis by structured diagnostic interview

(SCID).

- No medical contraindication to estrogen (this will include written documentation of a

recent normal gynecological exam with mammogram).

- Matched to depressed patients by age and menopausal status.

- Have no menstrual cycles or hormone therapy for at least one year or irregular menses

of either <21 days or 35 days for the previous six months to one year.

Exclusion Criteria for Healthy Subjects:

- Medical, neurologic or cerebrovascular disorder (CVA, seizure disorder, etc.).

- Evidence of substance use on urine toxicology screen done upon recruitment.

- Current treatment with psychoactive medication.

- Diabetes controlled by means other than diet.

- Use of alcohol within last month.

- Implanted metallic devices.

- Positive urine drug screen.

Yale University School of Medicine; Yale Program for Women's Reproductive Behavioral Health, New Haven, Connecticut 06511, United States

Related publications:

Weissman MM, Klerman GL. Sex differences and the epidemiology of depression. Arch Gen Psychiatry. 1977 Jan;34(1):98-111. Review.

Steiner M. Female-specific mood disorders. Clin Obstet Gynecol. 1992 Sep;35(3):599-611. Review.

Pariser SF. Women and mood disorders. Menarche to menopause. Ann Clin Psychiatry. 1993 Dec;5(4):249-54. Review.

Pearlstein TB. Hormones and depression: what are the facts about premenstrual syndrome, menopause, and hormone replacement therapy? Am J Obstet Gynecol. 1995 Aug;173(2):646-53. Review.

Nicol-Smith L. Causality, menopause, and depression: a critical review of the literature. BMJ. 1996 Nov 16;313(7067):1229-32. Review. Erratum in: BMJ 1996 Dec 14;313(7071):1516.

Schmidt PJ, Rubinow DR. Menopause-related affective disorders: a justification for further study. Am J Psychiatry. 1991 Jul;148(7):844-52. Review.

Arpels JC. The female brain hypoestrogenic continuum from the premenstrual syndrome to menopause. A hypothesis and review of supporting data. J Reprod Med. 1996 Sep;41(9):633-9. Review.

López-Jaramillo P, Terán E, Molina G, Rivera J, Lozano A. Oestrogens and depression. Lancet. 1996 Jul 13;348(9020):135-6. No abstract available.

Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol. 1991 Dec;78(6):991-5.

Schneider MA, Brotherton PL, Hailes J. The effect of exogenous oestrogens on depression in menopausal women. Med J Aust. 1977 Jul 30;2(5):162-3.

Thomson J, Oswald I. Effect of oestrogen on the sleep, mood, and anxiety of menopausal women. Br Med J. 1977 Nov 19;2(6098):1317-9.

Berlanga C. Potentiating effect of estrogen in a patient with treatment-resistant depression. J Clin Psychiatry. 1988 Dec;49(12):504. No abstract available.

Oppenheim G. A case of rapid mood cycling with estrogen: implications for therapy. J Clin Psychiatry. 1984 Jan;45(1):34-5.

Freeman EW, Purdy RH, Coutifaris C, Rickels K, Paul SM. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology. 1993 Oct;58(4):478-84.

Halbreich U, Petty F, Yonkers K, Kramer GL, Rush AJ, Bibi KW. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry. 1996 May;153(5):718-20.

Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994 Mar;51(3):199-214.

Mazure C, Nelson JC, Price LH. Reliability and validity of the symptoms of major depressive illness. Arch Gen Psychiatry. 1986 May;43(5):451-6.

Petty F, Kramer GL, Gullion CM, Rush AJ. Low plasma gamma-aminobutyric acid levels in male patients with depression. Biol Psychiatry. 1992 Aug 15;32(4):354-63.

Rothman DL, Petroff OA, Behar KL, Mattson RH. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5662-6.

Squires RF, Saederup E. Antidepressants and metabolites that block GABAA receptors coupled to 35S-t-butylbicyclophosphorothionate binding sites in rat brain. Brain Res. 1988 Feb 16;441(1-2):15-22.

Wisner KL, Wheeler SB. Prevention of recurrent postpartum major depression. Hosp Community Psychiatry. 1994 Dec;45(12):1191-6.

Starting date: July 1999
Ending date: June 2008
Last updated: February 28, 2008